Clinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT04940299 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 23, 2021
- Completion date
- December 31, 2027
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, locally advanced bladder carcinoma, locally advanced bladder urothelial carcinoma, locally advanced lung non-small cell carcinoma, locally advanced renal pelvis carcinoma, locally advanced renal pelvis urothelial carcinoma, locally advanced ureter urothelial carcinoma, locally advanced urethral urothelial carcinoma, malignant solid neoplasm, metastatic bladder carcinoma, metastatic bladder urothelial carcinoma, metastatic lung non-small cell carcinoma, metastatic melanoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral carcinoma, metastatic urethral urothelial carcinoma, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, stage iii bladder cancer ajcc v8, stage iii lung cancer ajcc v8, stage iii renal pelvis cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iii urethral cancer ajcc v8, stage iiia bladder cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib bladder cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv lung cancer ajcc v6, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8, stage iv urethral cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8, unresectable melanoma